A Meta-analysis of the correlation between frailty and postoperative adverse outcomes in ovarian cancer patients
10.3760/cma.j.cn115682-20230613-02373
- VernacularTitle:衰弱与卵巢癌患者术后不良结局关系的Meta分析
- Author:
Yaqin ZHU
1
;
Lihua ZHOU
;
Jia LIU
Author Information
1. 安徽医科大学护理学院，合肥 230032
- Keywords:
Ovarian neoplasms;
Frailty;
Cytoreduction surgical procedures;
Adverse outcomes;
Meta-analysis
- From:
Chinese Journal of Modern Nursing
2024;30(3):336-344
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To systematically review the correlation between frailty and postoperative adverse outcomes in ovarian cancer patients.Methods:The research on frailty and postoperative adverse outcomes in ovarian cancer patients was systematically searched in PubMed, Cochrane Library, Embase, Web of Science, China National Knowledge Infrastructure, WanFang Data, VIP, and China Biology Medicine. The search period was from database establishment to March 27, 2023. Two researchers independently conducted literature screening, quality evaluation, and data extraction, and conducted Meta-analysis using Stata 15.0 software.Results:A total of 17 studies were included. Meta-analysis showed that frailty increased the risk of total postoperative complications [ OR=1.84, 95% CI (1.53, 2.21), P<0.001], severe postoperative complications [ OR=2.34, 95% CI (1.80, 3.03), P<0.001], postoperative 30 day mortality [ OR=1.96, 95% CI (1.68, 2.28), P<0.001], and decreased overall survival [ OR=1.45, 95% CI (1.24, 1.69), P<0.001] in ovarian cancer patients, and it also increased the risk of Intensive Care Unit (ICU) transfer rate [ OR=2.11, 95% CI (1.97, 2.26), P<0.001], non-home discharge [ OR=1.57, 95% CI (1.48, 1.67), P<0.001], and readmission 30 days after surgery [ OR=1.12, 95% CI (1.03, 1.21), P=0.009]. Subgroup analysis showed that age, frailty assessment tools, and whether or not covariates were corrected had no effect on outcomes. Sensitivity analysis showed that all results were reliable. Conclusions:Frailty is a risk factor for postoperative complications, postoperative 30 day mortality, poor overall survival, ICU transfer rate, non-home discharge, and readmission 30 days after surgery in ovarian cancer patients. However, the research findings still need to be further validated through large-scale prospective cohort studies.
